Antibody-Drug Conjugates in Triple Negative Breast Cancer

Clin Breast Cancer. 2024 Apr;24(3):163-174. doi: 10.1016/j.clbc.2024.01.008. Epub 2024 Jan 20.

Abstract

Triple negative breast cancer (TNBC) accounts for 15%-20% of all breast cancer. It is a heterogeneous breast cancer subtype with a poor prognosis. Given these negative features, there is a need for new treatment options beyond conventional chemotherapy in both the early stage and palliative setting. Impressive results have been reported with antibody-drug conjugates (ADCs) that link a cytotoxic payload to a monoclonal antibody, such as sacituzumab govitecan and trastuzumab deruxtecan, in the metastatic stage. The focus of this review is to discuss completed and ongoing trials involving ADCs in TNBC.

Keywords: ADC; Sacituzumab govitecan; TNBC; Trastuzumab deruxtecan; Trop-2.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antineoplastic Agents* / therapeutic use
  • Breast Neoplasms* / drug therapy
  • Camptothecin / therapeutic use
  • Female
  • Humans
  • Immunoconjugates* / therapeutic use
  • Triple Negative Breast Neoplasms* / drug therapy
  • Triple Negative Breast Neoplasms* / pathology

Substances

  • Antineoplastic Agents
  • Camptothecin
  • Immunoconjugates
  • Antibodies, Monoclonal